Sabby Management’s Immunic IMUX Stock Holding History

Sabby Management’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-3	Closed	-$404K	–	346
2015 Q3	$404K	Buy	+3	New	+$15K	0.02%	312
2015 Q2	–	Hold	0	–	–	–	278

Other funds holding IMUX

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Sabby Management's IMUX Position: Q3 2020 in Review

Sabby Management sold out of Immunic (IMUX) in Q3 2020, closing a stake of 5,301 shares — an estimated $642K sold.

Sabby Management first reported a position in IMUX in Q3 2015 and held it in 2 quarters. The position peaked at $642K in Q2 2020. 66 funds tracked by Wall St. Rank hold IMUX as of Q3 2020.

Sabby Management reported no remaining Immunic position as of Q3 2020 after selling out during the quarter.
Sabby Management sold 5,301 Immunic shares in Q3 2020, an estimated $642K.
Sabby Management first reported a position in Immunic in Q3 2015 and held it in 2 quarters.
Sabby Management's Immunic position peaked at $642K in Q2 2020.
66 funds tracked by Wall St. Rank held Immunic as of Q3 2020.

Based on Sabby Management's 13F filing for Q3 2020, filed 16 Nov 2020.